Evotec AG (NASDAQ:EVTCY) released its quarterly earnings data on Thursday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by $0.03, Morningstar.com reports. The company had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.

Evotec AG (EVTCY) traded up 2.38% during trading on Friday, reaching $33.50. The company’s stock had a trading volume of 1,898 shares. Evotec AG has a 1-year low of $9.65 and a 1-year high of $34.32. The stock has a market capitalization of $2.34 billion and a PE ratio of 56.02. The stock has a 50 day moving average price of $30.47 and a 200 day moving average price of $23.66.

EVTCY has been the topic of several analyst reports. DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research note on Monday, July 31st. Deutsche Bank AG reiterated a “neutral” rating on shares of Evotec AG in a research note on Wednesday, May 3rd. Finally, Berenberg Bank lowered Evotec AG from a “buy” rating to a “hold” rating in a research note on Tuesday, June 6th.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/evotec-ag-nasdaqevtcy-posts-quarterly-earnings-results-misses-expectations-by-0-03-eps/1475196.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Earnings History for Evotec AG (NASDAQ:EVTCY)

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.